ArticleNature communications2026
Characterization of recombinase-based genetic parts and circuits using nanopore sequencing.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Characterization of recombinase-based genetic parts and circuits using nanopore sequencing.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Recombinases are versatile enzymes able to perform the precise insertion, deletion, and rearrangement of DNA and can act as a foundation for programmable genetic logic and memory. Crucial for their use are accurate measurements of function. However, these are often laborious, time-consuming, and costly to collect. To address this, we develop a semi-automated workflow that combines low-cost liquid handling robotics, multiplexed long-read nanopore sequencing, and a supporting computational analysis tool to enable the high-throughput and detailed characterization of recombinase parts and circuits when used in a variety of contexts and organisms. Our approach overcomes the limitations of typically used fluorescence-based assays and is able to monitor temporal dynamics, observe structural changes at nucleotide resolution, and unravel the internal workings of complex multi-state circuits. The ability to scale up and automate genetic circuit characterization is an essential step towards more rigorous biological metrology that can support the construction of predictive models for efficiently engineering biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.